State of Science Summit- Hematologic Cancer | Chaired by Dr. Gary J. Schiller | UCLA Jonsson Comprehensive Cancer Center

Commentary
Article

In Partnership With:

State of Science Summit- Hematologic Cancer | Chaired by Dr. Gary J. Schiller | UCLA Jonsson Comprehensive Cancer Center

State of Science Summit- Hematologic Cancer | Chaired by Dr. Gary J. Schiller | UCLA Jonsson Comprehensive Cancer Center

Speakers

  • Monica D. Mead, MD l UCLA Jonsson Comprehensive Cancer Center
  • Herbert A. Eradat, MD | UCLA Jonsson Comprehensive Cancer Center
  • Sven De Vos, MD, PhD l UCLA Jonsson Comprehensive Cancer Center
  • Wanxing Chai-Ho, MD | UCLA Jonsson Comprehensive Cancer Center
  • Caspian Oliai, MD, MS | UCLA Jonsson Comprehensive Cancer Center

Topics

  • Treatment Selection of BTK Inhibitors in MCL | Monica D. Mead, MD
  • Updates in CLL | Herbert A. Eradat, MD
  • Updates in DLBCL | Sven De Vos, MD, PhD
  • JAK Inhibitors for Myelofibrosis (MF) and PV | Gary J. Schiller, MD
  • Current Standards in Chronic GVHD (cGVHD) | Wanxing Chai-Ho, MD
  • Evolving Therapies in Myelodysplatic Syndromes (MDS) | Caspian Oliai, MD, MS

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Gottfried Konecny, MD
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Annie Im, MD, FASCO
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Elias Jabbour, MD
Related Content
Rebecca Klisovic, MD, of University Hospitals Seidman Cancer Center

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Karim Chamie, MD

N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC

May 1st 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024
Article
Gottfried E. Konecny, MD, medical oncologist, Department of Gynecologic Medical Oncology, lead clinician, gynecologic oncology, University of California, Los Angeles, UCLA Health Jonsson Comprehensive Cancer Center

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024
Article